(Q36615733)

15 August 2017

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy (English)

1 reference

15 August 2017

1 reference

F Barlési

1

1 reference

15 August 2017

C Tchouhadjian

2

1 reference

15 August 2017

C Doddoli

3

1 reference

15 August 2017

J-P Torre

4

1 reference

15 August 2017

P Astoul

5

1 reference

15 August 2017

J-P Kleisbauer

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

92

1 reference

15 August 2017

1

1 reference

15 August 2017

13-14

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6602296

15 August 2017

0 references

cites work

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361739

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361739

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361739

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361739

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361739

Tolerability of gefitinib in patients receiving treatment in everyday clinical practice

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361739

Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361739

Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2361739

20 September 2018

Identifiers

DOI

10.1038/SJ.BJC.6602296

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

15597098

1 reference